scholarly journals Long-chain acyl-CoA synthetase 2 knockdown leads to decreased fatty acid oxidation in fat body and reduced reproductive capacity in the insect Rhodnius prolixus

Author(s):  
Michele Alves-Bezerra ◽  
Eric L. Klett ◽  
Iron F. De Paula ◽  
Isabela B. Ramos ◽  
Rosalind A. Coleman ◽  
...  
2020 ◽  
Vol 11 ◽  
Author(s):  
Alexandre Umpierrez Amaral ◽  
Moacir Wajner

Deficiencies of medium-chain acyl-CoA dehydrogenase, mitochondrial trifunctional protein, isolated long-chain 3-hydroxyacyl-CoA dehydrogenase, and very long-chain acyl-CoA dehydrogenase activities are considered the most frequent fatty acid oxidation defects (FAOD). They are biochemically characterized by the accumulation of medium-chain, long-chain hydroxyl, and long-chain fatty acids and derivatives, respectively, in tissues and biological fluids of the affected patients. Clinical manifestations commonly include hypoglycemia, cardiomyopathy, and recurrent rhabdomyolysis. Although the pathogenesis of these diseases is still poorly understood, energy deprivation secondary to blockage of fatty acid degradation seems to play an important role. However, recent evidence indicates that the predominant fatty acids accumulating in these disorders disrupt mitochondrial functions and are involved in their pathophysiology, possibly explaining the lactic acidosis, mitochondrial morphological alterations, and altered mitochondrial biochemical parameters found in tissues and cultured fibroblasts from some affected patients and also in animal models of these diseases. In this review, we will update the present knowledge on disturbances of mitochondrial bioenergetics, calcium homeostasis, uncoupling of oxidative phosphorylation, and mitochondrial permeability transition induction provoked by the major fatty acids accumulating in prevalent FAOD. It is emphasized that further in vivo studies carried out in tissues from affected patients and from animal genetic models of these disorders are necessary to confirm the present evidence mostly achieved from in vitro experiments.


PEDIATRICS ◽  
1991 ◽  
Vol 87 (3) ◽  
pp. 328-333 ◽  
Author(s):  
William R. Treem ◽  
Jeffrey S. Hyams ◽  
Charles A. Stanley ◽  
Daniel E. Hale ◽  
Harris B. Leopold

Inherited defects in fatty acid oxidation, which have been described and diagnosed with increasing frequency in the last decade, are most commonly attributed to a deficiency in the activity of medium-chain acyl-CoA dehydrogenase. Few cases of the related enzyme defect of long-chain acyl-CoA dehydrogenase activity have been reported. An infant with documented long-chain acyl-CoA dehydrogenase deficiency is described with a detailed metabolic profile, long-term clinical follow-up, and response to treatment. This patient is compared with the seven previously published cases of this disorder in order to stress the unique features of the initial presentation, more subtle late manifestations of the disease, and clinical and biochemical differentiation from the more common medium-chain acyl-CoA dehydrogenase deficiency. This report stresses the enlarging spectrum of the clinical presentation and natural history of this defect in fatty acid oxidation.


1998 ◽  
Vol 95 (26) ◽  
pp. 15592-15597 ◽  
Author(s):  
D. M. Kurtz ◽  
P. Rinaldo ◽  
W. J. Rhead ◽  
L. Tian ◽  
D. S. Millington ◽  
...  

2016 ◽  
Vol 68 (Suppl. 3) ◽  
pp. 21-23
Author(s):  
Susan Winter ◽  
Neil R.M. Buist ◽  
Nicola Longo ◽  
Saro H. Armenian ◽  
Gary Lopaschuk ◽  
...  

The 1st International Carnitine Working Group concluded with a round table discussion addressing several areas of relevance. These included the design of future studies that could increase the amount of evidence-based data about the role of carnitine in the treatment of fatty acid oxidation defects, for which substantial controversy still exists. There was general consensus that future trials on the effect of carnitine in disorders of fatty acid oxidation should be randomized, double-blinded, multicentered and minimally include the following diagnoses: medium-chain acyl coenzyme A (CoA) dehydrogenase deficiency, very long-chain acyl-CoA dehydrogenase deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and mitochondrial trifunctional protein deficiency. Another area that generated interest was trials of carnitine in cardiomyopathy and, especially, the use of biomarkers to identify patients at greater risk of cardiotoxicity following treatment with anthracyclines. The possibility that carnitine treatment may lead to improvements in autistic behaviors was also discussed, although the evidence is still not sufficient to make any firm conclusions in this regard. Preliminary data on carnitine levels in children and adolescents with primary hypertension, low birth weight and nephrotic syndrome was also presented. Lastly, the panelists stressed that there remains an objective need to harmonize the terminology used to describe carnitine deficiencies (e.g., primary, secondary and systemic deficiency).


1997 ◽  
Vol 75 (2) ◽  
pp. 324-331 ◽  
Author(s):  
Christopher P. Patey ◽  
William R. Driedzic

Rainbow trout (Oncorhynchus mykiss) were acclimated to 5 or 15 °C. Hearts were excised and assayed for the activity of enzymes essential for fatty acid metabolism. The activity of long-chain acyl-CoA synthetase, the first enzyme required in either fatty acid oxidation or complex fatty acid synthesis, was increased following acclimation to low temperature. Total crude homogenates exhibited an increase in activity with either palmitate (0.037–0.047 μmol/(min∙g)), stearate (0.037–0.055 μmol/(min∙g)), or oleate (0.041–0.064 μmol/(min∙g)) as substrate. Mitochondrial preparations showed the greatest increase in activity with palmitate (0.486–0.962 nmol/(min∙g)) as substrate, whereas microsomal preparations exhibited the greatest increase in activity with oleate (0.976–1.933 nmol/(min∙g)) as substrate. The activity of carnitine acyl-CoA transferase I, which is located on the outer mitochondrial membrane and is required for fatty acid oxidation, increased following acclimation to low temperature with palmitoyl CoA (0.137–0.352 μmol/(min∙g)), stearoyl CoA (0.066–0.152 μmol/(min∙g)), or oleoyl CoA (0.137–0.224 μmol/(min∙g)) as substrate. The parallel increase in mitochondrial long-chain acyl-CoA synthetase and carnitine acyl-CoA transferase I is consistent with previous observations of an elevated capacity of heart to oxidize fatty acids as exogenous fuels following acclimation to low temperature. The increase in microsome-based long-chain acyl-CoA synthetase may contribute to heart growth at low temperature.


Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1239
Author(s):  
Khaled I. Alatibi ◽  
Judith Hagenbuchner ◽  
Zeinab Wehbe ◽  
Daniela Karall ◽  
Michael J. Ausserlechner ◽  
...  

Long-chain fatty acid oxidation disorders (lc-FAOD) are a group of diseases affecting the degradation of long-chain fatty acids. In order to investigate the disease specific alterations of the cellular lipidome, we performed undirected lipidomics in fibroblasts from patients with carnitine palmitoyltransferase II, very long-chain acyl-CoA dehydrogenase, and long-chain 3-hydroxyacyl-CoA dehydrogenase. We demonstrate a deep remodeling of mitochondrial cardiolipins. The aberrant phosphatidylcholine/phosphatidylethanolamine ratio and the increased content of plasmalogens and of lysophospholipids support the theory of an inflammatory phenotype in lc-FAOD. Moreover, we describe increased ratios of sphingomyelin/ceramide and sphingomyelin/hexosylceramide in LCHAD deficiency which may contribute to the neuropathic phenotype of LCHADD/mitochondrial trifunctional protein deficiency.


Sign in / Sign up

Export Citation Format

Share Document